Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19

Purpose

This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.

Conditions

  • SARS-CoV 2 Infection
  • Covid19

Eligibility

Eligible Ages
Between 18 Years and 100 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by RT-PCR) prior to enrollment

Exclusion Criteria

  • Under 18 years of age Concurrent eye infection or trauma unrelated to presence of SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample collection.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
SARS-CoV2 Positive Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus. A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus.
  • Diagnostic Test: SARS-CoV2 Autoantibody detection
    Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
Control Control tear and serum samples will be selected from Namida Lab's own biorepository.

Recruiting Locations

More Details

NCT ID
NCT04542980
Status
Completed
Sponsor
Namida Lab